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ABSTRACT 44 
Invasive nontyphoidal Salmonella (iNTS) infections are commonly associated with 45 
Plasmodium falciparum infections, but the immunologic basis for this linkage is poorly 46 
understood. We hypothesized that P. falciparum infection compromises the hosts’ humoral 47 
and cellular immunity to NTS which increases their susceptibility to iNTS infection. We 48 
prospectively recruited children aged between 6 and 60 months at a Community Health 49 
Centre in Blantyre, Malawi and allocated them to the following groups; febrile with 50 
uncomplicated malaria, febrile malaria-negative, non-febrile malaria-negative. S. 51 
Typhimurium (STm)-specific; serum bactericidal activity (SBA) and blood bactericidal 52 
activity (WBBA), complement C3 deposition and neutrophil respiratory burst activity 53 
(NRBA) were measured.  SBA to STm was reduced in febrile P. falciparum infected (Median 54 
-0.201og10, IQR [-1.85, 0.32]) compared to non-febrile malaria-negative (Median -55 
1.42log10, IQR [-2.0, -0.47], p=0.052). In relation to SBA, C3 deposition on STm was 56 
significantly reduced in febrile P. falciparum infected (Median 7.5%, IQR [4.1, 15.0]) 57 
compared to non-febrile malaria-negative (Median 29%, IQR [11.8, 48.0], p=0.048). WBBA 58 
to STm was significantly reduced in febrile P. falciparum infected (Median 0.25log10, IQR [-59 
0.73, 1.13], p=0.0001) compared to non-febrile malaria-negative (Median -1.0log10, IQR [-60 
1.68, -0.16]). In relation to WBBA, STm-specific NRBA was reduced in febrile P. 61 
falciparum infected (Median 8.8% IQR [3.7, 20], p=0.0001) compared to non-febrile 62 
malaria-negative (Median 40.5% IQR [33, 65.8]). P. falciparum infection impairs humoral 63 
and cellular immunity to STm in children during malaria episodes, which may explain the 64 
increased risk of iNTS observed in children from malaria endemic settings. The mechanisms 65 
underlying humoral immunity impairment are incompletely understood and should be 66 
explored further.  67 
 68 
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Word count: 247  69 
 70 
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 72 
INTRODUCTION 73 
Invasive infections with nontyphoidal Salmonella (NTS) serovars, principally Typhimurium 74 
and Enteritidis are estimated to cause over 2.1 million illnesses and 416,000 deaths per year 75 
(1). In malaria endemic settings, invasive NTS are commonly associated with current or 76 
convalescent episode of malaria, particularly severe malarial anemia (2, 3). Other factors 77 
associated with increased susceptibility to iNTS in children are immature immunity and 78 
malnutrition, while HIV infection is the driving force for iNTS susceptibility in adults (4, 5). 79 
About 6.5% of invasive bacterial infections (IBIs) occurs in P. falciparum infected children 80 
(6, 7), however in view of low sensitivity of blood cultures, P. falciparum infection could 81 
account for more than 50% of IBI in children living in malaria-endemic settings (8). Often 82 
children are diagnosed and treated for malaria while IBIs is unattended leading to poor health 83 
outcomes.  84 
 85 
The association between malaria and iNTS was first reported in 1920s (9). Biggs et al 86 
recently reported that iNTS and malaria co-infections were common in febrile pediatric in-87 
patients from a high malaria transmission area compared to those from a  low malaria 88 
transmission area in Tanzania (10). In contrast, S. Typhi bacteremia was uncommon in febrile 89 
pediatric in-patients from a high malaria transmission  area (10). In addition, the association 90 
between iNTS and malaria is observed in seasonal peaks during the rainy season (4, 5, 11, 91 
12). However, the immunologic basis for increased iNTS cases in malaria endemic setting is 92 
not fully understood.   93 
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The link between NTS and malaria in humans and mice are extensively covered in the 94 
reviews by Uche et al (13) and Takem et al (14) . Phagocytes (including neutrophils and 95 
monocytes) are key players in controlling rapid replicating NTS within the gut mucosa hence 96 
preventing the spread of NTS to systemic organs (15). Studies in both human and mice have 97 
shown that P. falciparum derived products such as hemozoin, heme and heme oxygenase-1 98 
mediate the reduction in phagocytosis and oxidative burst activities (16-18). Some have 99 
shown that during acute malaria, the pro-inflammatory cytokine IL-12 is reduced while anti-100 
inflammatory cytokine IL-10 is increased (19-22). The anti-inflammatory environment, 101 
coupled with reduced phagocytosis and oxidative burst activities during malaria, are thought 102 
to create a favorable environment for NTS replication within the gut mucosa and blood 103 
stream compartments.  However, the role of humoral immunity to NTS during P. falciparum 104 
infection has not been explored extensively, although its role in non-malarial children has 105 
been studied before (23-25).  106 
 107 
Immunoglobulin G (IgG) antibodies to NTS targeting lipopolysaccharide (LPS) are thought 108 
to confer some protection against NTS bacteremia in African children (23, 25, 26). 109 
Opsonizing anti-NTS-LPS IgG antibodies mediate NTS killing in a cell-free manner through 110 
the complement cascade membrane attack complex (MAC) and also facilitate killing by 111 
phagocytes which involves phagocytosis and respiratory burst mediated killing (24). We 112 
envisaged that exploring the role of humoral immunity to iNTS during malaria will broaden 113 
our understanding of iNTS and malaria association that has previously focused on cellular 114 
immunity. Therefore, we examined cell-free bactericidal activities and cellular bactericidal 115 
activities against NTS in a cohort of uncomplicated P. falciparum infected children. We show 116 
that during malaria, P. falciparum infection impairs serum bactericidal immunity to STm via 117 
altered complement C3 deposition on STm in addition to impairment of phagocytes 118 
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respiratory burst which has been known before, providing comprehensive explanation for 119 
increased susceptibility to iNTS during malaria in children.  120 
 121 
RESULTS 122 
Transient loss of serum bactericidal immunity to S. Typhimurium during current or 123 
convalescent P. falciparum infection 124 
We have previously shown that acquisition of serum bactericidal activity (SBA) to STm 125 
correlates with the decline in iNTS infections in childhood in individuals not infected with  P. 126 
falciparum (23, 25).  Therefore firstly, we examined the SBA to determine whether SBA to 127 
STm is reduced in P. falciparum infected children. We found that SBA to STm was reduced 128 
but did not reach statistical significance difference in children with acute malaria (Median -129 
0.201og10, IQR [-1.85, 0.32]) compared to non-febrile malaria-negative children (Median -130 
1.42log10, IQR [-2.0, -0.47], p=0.052) (Figure 1A). SBA to STm was significantly reduced 131 
in children with acute malaria (Median -0.201og10, IQR [-1.85, 0.32], p=0.0007) and at day 132 
14 in convalescence (Median -0.49log10, IQR [-2.0, 0.49] p=0.0054) compared to febrile 133 
malaria-negative children (Median -1.85log10, IQR [-2.85,-1.24]) (Figure 1A). SBA to STm 134 
at 30 day in convalescence (Median -1.851og10, IQR [-2.24, 0.06]) was similar to febrile 135 
malaria-negative children (Median -1.85log10, IQR [-2.85,-1.24], p=0.43) and non-febrile 136 
malaria-negative children (Median -1.42log10, IQR [-2.0, -0.47], p=0.39) (Figure 1A). 137 
Furthermore, in a subset of children we found that 6/23 (26%) had robust SBA to STm 138 
(ability to kill STm by at least ≥ -1.0 log10 change in STm cfu/ml) at acute malaria phase 139 
compared to 16/23 (69.5%) at day 30 in convalescence (Figure 1B). We also found that out of 140 
16 children that lacked robust SBA to STm at acute malaria phase, 10/16 (62.5%) attained 141 
robust SBA to STm at day 30 in convalescence.      142 
 143 
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We have previously shown that acquisition of SBA to STm correlates with age in healthy 144 
children (25).  We found that acquisition of robust SBA to STm correlated with age 145 
development in febrile non malaria children and in non-febrile malaria negative children SBA 146 
(spearman’s r =-0.43, p=0.0037 and r=-0.38, p=0.0086 respectively) (Figure 2B and 2A). 147 
Interestingly, we observed that during acute P. falciparum infection, at day 14 and 30 in 148 
convalescence, SBA to STm did not kill STm by at least  ≥ -1 log10 change in STm cfu/ml  149 
in  some older children (≥24 months considered serum immune to STm (23)) and SBA to 150 
STm poorly correlated with age (acute malaria spearman’s r=0.23, p=0.11, day 14 r=0.15, 151 
p=0.37 and day 30 spearman’s r=-0.16, p=0.39  respectively) (Figure 2C-2E).  152 
 153 
Since SBA to STm is mainly mediated by anti-STm IgG antibodies targeting LPS (23, 25). 154 
Un-expectedly, we found that SBA to STm in non-febrile malaria negative children poorly 155 
correlated with anti-STm-LPS IgG antibody titres (spearman’s r=0.038, p=0.81) while in 156 
febrile non-malaria children SBA correlated with anti-STm-LPS IgG antibody titres 157 
(spearman’s r= -0.34, p=0.03) (Figure 3A and 3B). Interestingly, we observed that during 158 
acute malaria, SBA to STm poorly correlated with anti-STm-LPS IgG antibody titres 159 
(spearman’s r=0.19, p=0.20) while the correlation of SBA to anti-STm-LPS IgG antibody 160 
titres was superior at day 14 and day 30 in convalescence, however this was only statistically 161 
significant at day 14 (spearman’s r= -0.37, p=0.04 and r= -0.29, p=0.15 respectively) (Figure 162 
3C-3E).  These findings suggest that P. falciparum infection induced the transient loss of 163 
serum bactericidal activity to STm in P. falciparum infected children which is independent of 164 
age and acquired antibody immunity.  165 
 166 
To explore this further, we randomly selected serum samples (n=10) of children (>24 months 167 
old) to examine levels of complement C3 and C5b-9 deposition during malaria (Figure 4). 168 
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Interestingly, we found that C3 deposition on STm was significantly lower in febrile P. 169 
falciparum infected children (Median 7.5%, IQR [4.1, 15.0]) compared to febrile malaria-170 
negative children (Median 60%, IQR [21.5, 71.5], p=0.003) and non-febrile malaria-negative 171 
children (Median 29%, IQR [11.8, 48.0], p=0.048) (Figure 4C and 4E). C3 deposition was 172 
also lower in febrile P. falciparum infected children (Median 7.5%, IQR [4.1, 15.0]) 173 
compared to day 30 in convalescence (Median 19%, IQR [12.1, 58.8], p=0.027) and was 174 
similar at day 14 in convalescence (Median 19.5%, IQR [10.7, 28.7], p=0.113) (Figure 4C-175 
4D).  176 
C5b-9 deposition on STm was significantly lower in febrile P. falciparum infected children 177 
(Median 21%, IQR [9.6, 31.0]) compared to febrile malaria-negative children (Median 34%, 178 
IQR [29, 74.5], p=0.012) but was not significantly different from that seen in non-febrile 179 
malaria negative children (Median 28%, IQR [14.35, 40.8], p=0.57). There was no significant 180 
differences in C5b-9 deposition on STm in febrile P. falciparum infected children (Median 181 
21%, IQR [9.6, 31.0]) compared to day14 (Median 24%, IQR [24.8, 46.5], p=0.084) and day 182 
30 in convalescence (Median 38%, IQR [29, 64], p=0.084) (Figure 4E-4F).  Taken together, 183 
this suggests a transient increase in consumption of C3 complement component during acute 184 
malaria which rebound to levels comparable to non-malaria children by day 14 in malaria 185 
convalescence.  186 
 187 
 188 
Serum is a pre-requisite for blood cells killing of S. Typhimurium 189 
S. Typhimurium is a facultative intracellular organism that requires the action of both cellular 190 
and humoral immunity to be effectively controlled. We therefore examined if whole blood 191 
killing of STm was also reduced during P. falciparum infection. We found that whole blood 192 
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bactericidal activity (WBBA) to STm was reduced during malaria at acute stage (Median 193 
0.25log10, IQR [-0.73, 1.13], p=0.0001), day  14 (Median -0.511og10, IQR [-1.53, 0.57], 194 
p=0.110)   and day 30 in convalescence (Median -0.191og10, IQR [-0.96,0.64], p=0.009) and 195 
in febrile malaria negative children (Median 0.18log10, IQR [-0.66, 0.87], p=0.004)  196 
compared to  non-febrile malaria-negative children (Median  -1.0log10, IQR [-1.68, -0.16]) 197 
(Figure 5A).  198 
 199 
Humoral immunity enhances intracellular killing of STm (24).  We observed that washed 200 
blood cells bactericidal activity (WBCBA) to STm during malaria, in febrile malaria-negative 201 
children and non-febrile malaria-negative children was abrogated in all washed blood cells 202 
conditions examined (Figure 5A-B). To determine if serum mediated immunity is required 203 
for efficient washed blood cells killing of STm. We examined the assay after STm was 204 
opsonised with autologous serum, and we found that killing of STm was partially restored 205 
(Figure 5A-5C). We show that WBBA to STm is reduced during malaria and in febrile illness 206 
in children and that serum opsonisation is be essential for cellular killing.   207 
 208 
Reduced S. Typhimurium-specific neutrophil respiratory burst in malaria and febrile 209 
non-malaria children 210 
To identify the specific bactericidal function that was altered in children with malaria and 211 
febrile illness, we examined neutrophils respiratory burst activity (NRBA) as it is a key 212 
mechanism for intracellular pathogen killing. We found that NRBA was significantly reduced 213 
in children during acute malaria (Median 8.8%, IQR [3.7, 20], p=0.0001) and also in febrile 214 
malaria-negative children (Median 9.4%, IQR [4.4, 19.5], p=0.0001) compared to non-febrile 215 
malaria-negative children (Median 40.5%, IQR [33, 65.8]) (Figure 6A and 6B). We observed 216 
that in P. falciparum infected children, there was a modest trend for improved respiratory 217 
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burst at day 14 (Median 17%, IQR [5.1, 31.5], p=0.135) and day 30 (Median 17%, IQR [6.1, 218 
32], p=0.042) in convalescence compared to the acute malaria phase (Median 8.8%, IQR 219 
[3.7, 20]) (Figure 6B), but that even at 1 month there remained a significant defect. This 220 
shows that both malarial and non-malarial febrile children have impaired NRBA to STm. The 221 
pattern over time was similar to that seen for whole-blood killing, in keeping with oxidative 222 
burst being a dominant mechanism for the observed whole blood bacterial killing.  223 
 224 
DISCUSSION 225 
This study extends our understanding of how P. falciparum infection compromises 226 
phagocyte-dependent immunity to NTS in children (16-18), which provides additional 227 
explanation to the observed increased children’s susceptibility to iNTS in malaria endemic 228 
settings. Our study describes the transient loss of serum bactericidal immunity to iNTS during 229 
current or convalescent P. falciparum infection in children. This loss of serum bactericidal 230 
immunity was specific to children who were febrile from malaria compared to other causes of 231 
fever. P. falciparum infection appears to compromise serum bactericidal immunity to iNTS in 232 
older children, and does not correlate with pre-existing IgG antibodies to STm LPS. This may 233 
likely be caused by the increased consumption of C3 complement component during P. 234 
falciparum infection.  235 
 236 
In this study, we have demonstrated the transient loss of bactericidal humoral immunity to 237 
STm in children with current or convalescent P. falciparum infection. The loss in bactericidal 238 
SBA to STm was independent of age and anti-STm LPS IgG antibody titres during acute 239 
malaria and day 14 convalescent malaria, and robust SBA to STm was restored after 30 days 240 
convalescence. This was explored further by examining complement components deposition 241 
on STm. Consistent with previous findings (27), we found that deposition of mainly C3 242 
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complement component was transiently reduced during the acute phase of P. falciparum 243 
infection and  rebound  at  days 14 and  30 in malaria convalescence to levels  comparable to 244 
non-malaria controls. This is in keeping with lack of robust SBA to STm during acute malaria 245 
in some children with high anti-STm LPS-IgG antibody titres. Increased consumption of 246 
complement components,  particularly C3, during acute malaria as observed in the current 247 
study and other studies  (27), which are crucial for antibody dependent-complement killing of 248 
gram negative bacteria (23, 28), may favour the proliferation of STm.  We observed that at 249 
day 14 in malaria convalescent children, SBA to STm remained poor despite complement 250 
proteins C3 on STm rebounding to normal levels, suggesting that other factors may be 251 
involved in compromising serum bactericidal immunity during malaria and this needs to be 252 
investigated further. P. falciparum has also developed complement killing escape strategies, 253 
it is possible that serum killing is abrogated during malaria via  P. falciparum recruitment of 254 
factor H protein which prevents complement cascade activation via the C3b (29-31), 255 
ultimately blocking complement mediated NTS lysis. Furthermore, P. falciparum infection 256 
may compromise humoral immunity to NTS via reduction of antibody opsonisation capacity 257 
as observed in some studies (32), as well as defective complement cascade activation. This 258 
observation suggests that in children from settings where exposure to NTS is frequent, and 259 
malaria is highly endemic, humoral bactericidal immunity may be lost during repeated 260 
malaria episodes, increasing overall susceptibility to iNTS by favouring NTS proliferation 261 
and systemic infection.  262 
 263 
We have showed that WBBA to STm is reduced in both P. falciparum infected and febrile 264 
malaria-negative children. Consistent with previous observations (24), our findings indicate 265 
that serum immunity plays a crucial role in both cell-free and intracellular killing of NTS. 266 
These findings provide support of antibody-based NTS vaccine development strategies, as 267 
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they are likely to elicit both extracellular and intracellular protection against iNTS. 268 
Neutrophil respiratory burst constitutes a key mechanism of intracellular effector function for 269 
Salmonella killing (33). Consistent with results of previous studies (16-18, 21), we have 270 
shown that NRBA to STm is reduced in both P. falciparum infected and febrile malaria-271 
negative children compared to non-febrile malaria-negative children. It has long been known 272 
that P. falciparum infection derived products including heme, heme oxygenase and hemozoin 273 
compromises neutrophils and monocytes effector functions in both humans and mice (16-18, 274 
21, 34). In contrast to transient loss of serum killing to STm, we observed that both NRBA 275 
and WBBA were reduced for a period longer than 30 days in malaria convalescent children. 276 
This is in keeping with previous observation (18).  Surprisingly, we found that NRBA was 277 
also reduced in febrile malaria-negative children compared to non-febrile malaria negative 278 
children. How non-malarial febrile illness compromises neutrophil respiratory burst is not 279 
clear. In this study, we did not confirm the aetiology of non-malarial febrile illnesses. 280 
Identifying the causes of these febrile illnesses may provide insights into the mechanisms 281 
behind impaired neutrophils respiratory burst. We recommend further investigations into the 282 
contribution of reduced C3 levels during acute phase of malaria to poor NRBA and WBBA to 283 
STm which was not explored in our current study. These findings suggest that the loss of 284 
intracellular killing of NTS in P. falciparum infected and non-malarial febrile children is 285 
likely due to impaired neutrophil respiratory burst activity.  286 
 287 
 288 
Conclusion 289 
We have demonstrated that P. falciparum infection transiently compromises the humoral 290 
immunity to NTS in children extending our knowledge that P. falciparum infection 291 
compromises cellular immunity to NTS. This study broadens our understanding of the 292 
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immunologic basis of increased susceptibility to iNTS during current or convalescent 293 
malaria, and the epidemiological association of malaria and iNTS in malaria endemic regions. 294 
The global immune defects induced by P. falciparum infection may render children from 295 
malaria endemic regions at risk of not only iNTS but also other enteric gram negative 296 
bacteria(35). Our study further highlights the need to improve management of concurrent 297 
malaria and IBI infections, particularly by developing rapid diagnostic test for IBIs, ideally to 298 
be run in parallel with malaria rapid diagnostic test. This could significantly improve the 299 
identification of malaria and IBIs, promote rational prescribing of antimicrobial agents and 300 
improve health outcomes. 301 
 302 
METHODS AND MATERIALS 303 
Recruitment of Study Participants and Follow-up 304 
We recruited 154 children aged 6 to 60 months at a Community Health Centre in Blantyre, 305 
Malawi from January 2016 to August 2016. Study participants comprised 59 febrile children 306 
presenting with uncomplicated malaria; 49 febrile malaria-negative children; and 46 non-307 
febrile malaria-negative children (Table 1). P. falciparum infected children were followed up 308 
at day 14 (n=42) and day 30 (n=41) during convalescence. Uncomplicated malaria group was 309 
comprised of children with acute phase of P. falciparum infection and presented to hospital 310 
for medical care, they were febrile (> 37.8 ºC) at the time of recruitment, had positive malaria 311 
rapid diagnostic test and positive malaria blood film, Blantyre Coma Score of 5 (36), 312 
haemoglobin (Hb) >5g/dl and serum glucose ≥45 mg/dl. Children with a positive HIV 313 
antibody test, severe anaemia (Hb ≤5 g/dl), malnutrition (weight for height Z-score <-2) or 314 
other chronic illness were excluded from the study. A 3 ml venous blood sample was 315 
collected from each participant at recruitment and during follow-up. Participants presenting 316 
with uncomplicated malaria were treated according to Malawi Government guidelines, before 317 
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blood sample collection. Ethical approval for the study was obtained from College of 318 
Medicine Research Ethics Committee (Protocol number P.08/15/1785) and written informed 319 
consent was obtained from parents or guardians of participating children. 320 
 321 
Quantification of STm-specific SBA 322 
Serum bactericidal activity (SBA) assays were performed as previously described (23). 323 
Briefly, serum or phosphate buffer saline (PBS) was mixed with STm D23580 (37) adjusted 324 
to 1.0x10⁶cfu/ml and incubated at 370C for 180 minutes. Test samples were serially diluted 325 
and plated in triplicate on Luria Bertani agar. Colony count of STm was done after 24 hours 326 
of incubation. Log 10 change in STm cfu/ml from the baseline was reported. 327 
 328 
Quantification of STm-specific whole blood and washed blood cells killing  329 
Three conditions were prepared as previously described (24); for condition 1, whole blood 330 
was used in whole blood bactericidal assay (WBBA), for condition 2, whole blood was 331 
washed twice with RPMI 1640 at 1,000 rpm for 10 minutes before using in a washed blood 332 
cells bactericidal assay (WBCBA). For condition 3, STm adjusted at 1.0x107 cfu/ml was first 333 
opsonised with 1:10 serum from each participating child for 20 minutes at room temperature 334 
(RT) before challenging washed blood cells in a washed blood cells and serum-opsonised 335 
assay (WBCSOA).  All conditions were challenged with STm adjusted at a final 336 
concentration of 1.0x10⁶cfu/ml. Colony counts were performed as described for the SBA 337 
experiment above. 338 
 339 
Quantification of anti-STm IgG antibody titre by ELISA 340 
These experiments were performed as previously described (25). Briefly, ELISA plates 341 
(Nunc-Immuno) were coated overnight with 100µl of carbonate-bicarbonate buffer (Sigma 342 
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Aldrich) per well containing 7.5µg/ml STm-LPS antigen (ALEXIS Biochemicals). Plates 343 
were washed with PBS containing 0.05% Tween 20 and blocked with 200µl/well blocking 344 
buffer (PBS/1% BSA) for 1 hour at 37°C. Test serum at 1:20 in dilution buffer (PBS/0.05% 345 
Tween 20/1% BSA) was serially diluted 3-fold and incubated at 37°C for 1 hour. After 346 
washing, 100µl of 1:2000 secondary Goat Anti-human IgG-AP antibodies (Southern Biotech) 347 
were added and incubated for 1 hour at 37°C. Finally, after washing, 100µl of 348 
SIGMAFAST™ p-Nitrophenyl phosphate substrate was added to each plate and read after 30 349 
minutes using a Bio Tek reader ELx800 (Bio Tek Instruments, USA) at 405nm. 350 
 351 
Quantification of complement components binding on the surface of STm 352 
These experiments were performed as previously described (23, 28), 5µl of STm at 2x108 353 
cfu/ml was gently mixed with 45µl of undiluted serum or PBS (control) at RT for 20 minutes. 354 
Samples were washed twice with 1ml PBS by spinning for 5 minutes at 3,300g. 2µl of anti-355 
C3c FITC conjugated antibody (Abcam) was added to 50µl of pellet to measure C3 356 
deposition. 1µl of anti-C5b-9 neo-epitope antibody (Abcam) and 2µl of rabbit-anti-mouse 357 
FITC conjugated antibody (Abcam) were added to 50µl of pellet to measure MAC. Samples 358 
were washed twice with 1ml PBS after 20 minutes incubation at RT and fixed with 200μl 1% 359 
formaldehyde PBS. Samples were acquired on CyAN ADP flow cytometer (Beckman 360 
Coulter) and analysed using Flow Jo version 7.6.5. 361 
 362 
Quantification of Neutrophil Respiratory Burst 363 
Phagoburts test kit (Glycotope Biotechnology) was modified to measure neutrophil 364 
respiratory burst as previously described (24). Whole blood (45µl) was incubated on ice for 365 
10 minutes then stimulated with serum opsonised STm at 1.0x108 cfu/ml or wash solution 366 
containing instalmed-salts (control).  Samples were then incubated for 10 minutes at 37 °C to 367 
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allow phagocytosis followed by 10 minutes incubation at 37°C after adding 368 
dihydrorhodamine 123 to promote oxidation. The reaction was stopped by 1:10 lysing 369 
solution for 20 minutes at RT. Samples were acquired on CyAN ADP flow cytometer 370 
(Beckman Coulter) and analysed using Flow Jo version 7.6.5. 371 
Statistical Analyses  372 
Statistical analyses were performed using GraphPad Prism version 5 (GraphPad Software, 373 
USA). Log10 change in bactericidal activity to STm, percentage of neutrophil respiratory 374 
burst positive cells or complement deposition were examined for normality of distribution 375 
using D’Agostino and Pearson omnibus normality test. Nonparametric data was compared 376 
using Mann-Whitney U test or Wilcoxon signed ranked test for paired t test. Median and 377 
interquartile range (IQR) were reported, and p value of less than 0.05 was considered 378 
statistically significant. Spearman’s correlation coefficient r was used to determine 379 
relationships between bactericidal activity and age and anti-STm LPS IgG antibody titres 380 
during malaria.  381 
 382 
 383 
 384 
 385 
 386 
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TABLES 544 
 545 
Table 1: Study Participants’ demographic and clinical features  546 
 547 
 During malaria Non malaria controls 
 Acute 
n= 59 
2 weeks 
n=42 
1 month 
n=41 
Febrile 
n=49 
Non febrile 
n=46 
Female participants 
(%) 
34 (58) 26 (62) 25 (61) 27(55) 15 (39) 
Median age in 
months (range) 
22.8 
(6-59.8) 
23.5 
(6.6-60.2) 
24.1 
(7-61) 
22.8 
(6-59.3) 
21.9 
(6.7-50.7) 
Median weight in kg 
(range) 
10.2 
(6.9-17) 
10.5 
(7 -16.1) 
10.1 
(7.1-16.3) 
10.1 
(6.9-15.4) 
10.5 
(7.1-15.5) 
Median height in cm 
(range) 
84 
(66-113) 
85 
(75-113) 
85 
(75.6-113) 
84.5 
(74-104) 
82.5 
(64-106) 
Median MUAC  in 
cm (range) 
14 
(10.2-19) 
13.8 
(10-18.7) 
13.95 
(10.4-18.8) 
13.4 
(10-16.2) 
14.2 
(10.2-17.5) 
Median Hb in g/dl 
(range) 
9.5 
(5.9-12.3) 
9.7 
(7.3-
12.4) 
10.3 
(8.4-12.7) 
10.8 
(7.9-18.7) 
11 
(5.2-13.6) 
Median absolute 
lymphocytes 
x10ᶺ3/μl (range) 
3.4 
(0.9-9.8) 
5.3 
(2.2-9.2) 
5.3 
(1.7-15.2) 
4.2 
(1.2-14.9) 
5.4 
(2.2-69.2) 
Median absolute 
neutrophils x10ᶺ3/μl 
(range) 
3.7 
(0.93-11.4) 
2.8 
(1.2-3.9) 
2.8 
(0.5-5.9) 
3.6 
(0.2-19.9) 
2.3 
(0.18-22.2) 
Splenomegaly (%) 20 (39) 1 (2.4) 0 (0) 4(8.2) 1(2.6) 
Cough (%) 24(40.6) 9 (21.4) 9 (22) 29(59) 0(0) 
Shortness of breath 
(%) 
1(1.7) 0 (0) 0 (0) 13(26.5) 0(0) 
Vomit (%) 21(35.6) 1(2.4) 2(4.9) 25(51) 0(0) 
Diarrhoea (%) 14 (23.7) 0(0) 2(4.9) 14(28.6) 0(0) 
 548 
 549 
 550 
 551 
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LEGENDS 552 
 553 
Figure 1: Transient loss of serum bactericidal immunity to S. Typhimurium during 554 
current and convalescent P. falciparum infection 555 
Serum bactericidal activity was reported as log10 change in STm cfu/ml from the baseline 556 
and this was plotted as indicated during malaria and in controls. Red bars represent the 557 
median and statistical differences were determined by Mann-Whitney U test (Fig 1A). Serum 558 
bactericidal activity during malaria was linked (Fig 1B). 559 
 560 
 561 
Figure 2: Relationship between serum bactericidal activity to S. Typhimurium and age 562 
during malaria    563 
Serum bactericidal activity was reported as log10 change in STm cfu/ml from the baseline 564 
and this was plotted against age in months as indicated in controls and during malaria. 565 
Spearman’s r correlation coefficient and p value was reported. 566 
 567 
 568 
Figure 3: Relationship between serum bactericidal activity to S. Typhimurium and anti-569 
IgG antibody targeting S. Typhimurium LPS    570 
Serum bactericidal activity to STm was plotted anti-IgG antibodies targeting STm LPS in 571 
controls and during malaria as indicated. Spearman’s r correlation coefficient and p value was 572 
reported. 573 
 574 
 575 
 576 
 577 
 578 
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Figure 4:  Reduced C3 deposition to S. Typhimurium during acute phase of P. 579 
falciparum infection in children 580 
Serum (n=10) was randomly selected from >24 months children donors during malaria and 581 
controls.  Serum bactericidal activity was reported as log10 change in STm cfu/ml from the 582 
baseline and this was plotted as indicated during malaria and in controls (Fig 4A).  Serum 583 
bactericidal activity during malaria was linked (Fig 4B). Proportion of C3 and C5b-9 584 
deposition on S. Typhimurium during malaria was linked (Fig 4D and Fig 4F). Red bars 585 
represent the median and statistical differences were determined by Wilcoxon signed rank 586 
test and Mann-Whitney U test. 587 
 588 
 589 
Figure 5: Reduced blood cells killing of S. Typhimurium in malaria and non-malarial 590 
febrile children 591 
Whole blood, washed blood or serum opsonised washed blood bactericidal activity was 592 
reported as log10 change in STm cfu/ml from the baseline and plotted as indicated during 593 
malaria and in controls. Red bars represent the median and statistical differences were 594 
determined by Mann-Whitney U test. 595 
 596 
 597 
Figure 6:  Reduced S. Typhimurium specific neutrophil respiratory burst activity in 598 
malaria and non-malarial febrile children 599 
The representative gating strategy of neutrophils using forward scatter (FSC) and side scatter  600 
(SSC) expression followed by neutrophil respiratory burst activity plots in unstimulated or 601 
STm stimulated is shown (Fig 6A). Percentage of STm-specific neutrophils respiratory burst 602 
positive cells were plotted during malaria and in controls as indicated (Fig 6B).  Red bars 603 
represent the median and statistical differences were determined by Mann-Whitney U test. 604 
 o
n
 M
ay 22, 2017 by guest
http://cvi.asm
.org/
D
ow
nloaded from
 
Acute 2 wks 1 mo Febrile Non febrile
-4
-3
-2
-1
0
1
2
3
4
5
6
During malaria Controls
p=0.0007
p=0.0054
p=0.0521
 
Lo
g1
0 
ch
a
n
ge
in
S.
Ty
ph
im
u
riu
m
 
cf
u
/m
l
Acute 2wks 1 mo
-4
-3
-2
-1
0
1
2
3
4
5
6
      During malaria
 
Lo
g1
0 
ch
a
n
ge
in
S.
Ty
ph
im
u
riu
m
 
cf
u
/m
l
A B
Figure 1 
 o
n
 M
ay 22, 2017 by guest
http://cvi.asm
.org/
D
ow
nloaded from
 
0 6 12 18 24 30 36 42 48 54 60 66 72
-4
-3
-2
-1
0
1
2
3
4        1mo convalescence
r=-0.16
Age in months
 
Lo
g1
0 
ch
a
n
ge
in
S.
Ty
ph
im
u
riu
m
 
cf
u
/m
l
A
0 6 12 18 24 30 36 42 48 54 60 66 72
-4
-3
-2
-1
0
1
2
3
4        Acute
r=0.23
Age in months
 
Lo
g1
0 
ch
a
n
ge
in
S.
Ty
ph
im
u
riu
m
 
cf
u
/m
l
0 6 12 18 24 30 36 42 48 54 60 66 72
-4
-3
-2
-1
0
1
2
3
4        2wks convalescence
r=0.15
Age in months
 
Lo
g1
0 
ch
a
n
ge
in
S.
Ty
ph
im
u
riu
m
 
cf
u
/m
lC D
p=0.10 p=0.37
p=0.39
0 6 12 18 24 30 36 42 48 54 60 66 72
-4
-3
-2
-1
0
1
2
3
4        Non malaria febrile
r=-0.43
Age in months
 
Lo
g1
0 
ch
a
n
ge
in
S.
Ty
ph
im
u
riu
m
 
cf
u
/m
lB
p=0.04
0 6 12 18 24 30 36 42 48 54 60 66 72
-4
-3
-2
-1
0
1
2
3
4        Non malaria/healthy
r=-0.38
Age in months
 
Lo
g1
0 
ch
a
n
ge
in
S.
Ty
ph
im
u
riu
m
 
cf
u
/m
l
E
p=0.009
Figure 2 
 o
n
 M
ay 22, 2017 by guest
http://cvi.asm
.org/
D
ow
nloaded from
 
1 10 100 1000
-4
-3
-2
-1
0
1
2
3
4 Acute
r=0.19
Anti-STm LPS IgG titre
 
Lo
g1
0 
ch
a
n
ge
in
S.
Ty
ph
im
u
riu
m
 
cf
u
/m
l
1 10 100 1000
-4
-3
-2
-1
0
1
2
3
4 2wks convalescence
r=-0.37
Anti-STm LPS IgG titre
 
Lo
g1
0 
ch
a
n
ge
in
S.
Ty
ph
im
u
riu
m
 
cf
u
/m
l
1 10 100 1000
-4
-3
-2
-1
0
1
2
3
4 1mo convalescence
r=-0.29
Anti-STm LPS IgG titre
 
Lo
g1
0 
ch
a
n
ge
in
S.
Ty
ph
im
u
riu
m
 
cf
u
/m
l
1 10 100 1000
-4
-3
-2
-1
0
1
2
3
4 Non malaria febrile
r=-0.34
Anti-STm LPS IgG titre
 
Lo
g1
0 
ch
a
n
ge
in
S.
Ty
ph
im
u
riu
m
 
cf
u
/m
l
1 10 100 1000
-4
-3
-2
-1
0
1
2
3
4 Non malaria/healthy
r=0.038
Anti-STm LPS IgG titre
 
Lo
g1
0 
ch
a
n
ge
in
S.
Ty
ph
im
u
riu
m
 
cf
u
/m
lA
C
B
D
E
p=0.20
p=0.04
p=0.15
p=0.03p=0.81
Figure 3 
 o
n
 M
ay 22, 2017 by guest
http://cvi.asm
.org/
D
ow
nloaded from
 
ADC
B
E F
Acute 2 wks 1 mo Febrile Non febrile
-4
-3
-2
-1
0
1
2
During malaria   Control
Lo
g1
0 
ch
an
ge
 
in
 
S.
 
Ty
ph
im
u
riu
m
 
cf
u
/m
l
Acute 2 wks 1 mo
-4
-3
-2
-1
0
1
2
During malaria
Lo
g1
0 
ch
a
n
ge
 
in
 
S.
 
Ty
ph
im
u
riu
m
 
cf
u
/m
l
Acute 2 wks 1 mo Febrile Non febrile
0
20
40
60
80
100
During malaria   Control
p=0.003
p=0.048
p=0.027
C3
 
de
po
si
tio
n
 
o
n
 
S.
 
Ty
ph
im
u
riu
m
 
%
Acute 2 wks 1 mo Febrile Non febrile
0
20
40
60
80
100
During malaria   Control
p=0.012
p=0.57
p=0.084
C5
b-
9 
de
po
si
tio
n
 
o
n
 
S.
 
Ty
ph
im
u
riu
m
 
%
Acute 2 wks 1 mo
0
20
40
60
80
100
During malaria
C3
 
de
po
si
tio
n
 
o
n
 
S.
 
Ty
ph
im
u
riu
m
 
%
Acute 2 wks 1 mo
0
20
40
60
80
During malaria
C5
b-
9 
de
po
si
tio
n
 
o
n
 
S.
 
Ty
ph
im
u
riu
m
 
%
Figure 4 
 o
n
 M
ay 22, 2017 by guest
http://cvi.asm
.org/
D
ow
nloaded from
 
Acute 2 wks 1 mo Febrile Non febrile
-4
-3
-2
-1
0
1
2
3
4
5
6
During malaria Controls
p=0.0001
p=0.0004
       Whole blood + STm
Lo
g1
0 
ch
an
ge
 
in
 
S.
 
Ty
ph
im
u
riu
m
 
cf
u
/m
l
Acute 2 wks 1 mo Febrile Non febrile
-4
-3
-2
-1
0
1
2
3
4
5
6
7
8
During malaria                  Controls
  Washed blood + STm
Lo
g1
0 
ch
a
n
ge
in
 
S.
 
Ty
ph
im
u
riu
m
 
cf
u
/m
l
Acute 2 wks 1 mo Febrile Non febrile
-4
-3
-2
-1
0
1
2
3
4
5
6
During malaria Control
                    Washed blood + serum opsonised STm
Lo
g1
0 
ch
a
n
ge
in
 
S.
 
Ty
ph
im
u
riu
m
 
cf
u
/m
l
A B
C
Figure 5 
 o
n
 M
ay 22, 2017 by guest
http://cvi.asm
.org/
D
ow
nloaded from
 
Serum opsonised STm
Acute 2 wks 1 mo Febrile Non febrile
0
20
40
60
80
100
During malaria   Controls
p=0.0001
p=0.0001
p=0.0001
Ne
u
tro
ph
ils
Re
sp
ira
to
ry
 
Bu
rs
t %SS
C
SS
C
FSC
FITC  (Respiratory  burst) 
Unstimulated STm stimulated  
0.3% 71%
Neutrophils 
12%
A B
Figure 6 
 o
n
 M
ay 22, 2017 by guest
http://cvi.asm
.org/
D
ow
nloaded from
 
